Principi N, Marchisio P
Department of Pediatrics (IV), Milan University Medical School, Italy.
J Chemother. 1998 Apr;10(2):108-13. doi: 10.1179/joc.1998.10.2.108.
In a multicenter, randomized, open comparison of meropenem to ceftazidime as empiric treatment of severe acute infections, 185 children (1 mo-15 years old, mean 65.4 mo) were enrolled. Meropenem (20 mg/kg t.i.d. i.v.) was given to 98 and ceftazidime (10-30 mg/kg t.i.d. i.v.) to 87 children, generally for 5 to 10 days (mean: 6.9 for meropenem and 7.5 for ceftazidime). Clinical response was evaluated at the beginning and at the end of therapy and 4 weeks later (follow-up). Clinical response was deemed satisfactory at the end of therapy in 96.7% of the patients treated with meropenem and in 95.3% of those who received ceftazidime without any statistically significant difference. One relapse occurred in a meropenem-treated patient at the follow-up clinical assessment. The baseline infecting organism was eradicated or presumed eradicated at the end of therapy in 14/16 patients treated with meropenem and in 14/15 treated with ceftazidime. The incidence of drug-related adverse events (mostly a slight increase in liver enzymes) was 9.2% in the meropenem group and 4.6% in the ceftazidime group. Our data show that meropenem is as effective as ceftazidime in the empiric treatment of severe infections in infants and children.
在一项多中心、随机、开放的比较美罗培南与头孢他啶作为严重急性感染经验性治疗药物的研究中，纳入了185名儿童（年龄1个月至15岁，平均65.4个月）。98名儿童接受美罗培南（静脉注射，20mg/kg，每日3次）治疗，87名儿童接受头孢他啶（静脉注射，10 - 30mg/kg，每日3次）治疗，通常治疗5至10天（美罗培南组平均6.9天，头孢他啶组平均7.5天）。在治疗开始时、治疗结束时以及4周后（随访）评估临床反应。接受美罗培南治疗的患者中，96.7%在治疗结束时临床反应被认为满意，接受头孢他啶治疗的患者中这一比例为95.3%，两者无统计学显著差异。在随访临床评估时，一名接受美罗培南治疗的患者出现复发。治疗结束时，接受美罗培南治疗的16名患者中有14名、接受头孢他啶治疗的15名患者中有14名的基线感染病原体被根除或推测被根除。美罗培南组药物相关不良事件的发生率（主要是肝酶略有升高）为9.2%，头孢他啶组为4.6%。我们的数据表明，在婴儿和儿童严重感染的经验性治疗中，美罗培南与头孢他啶同样有效。
